Nycomed's TachoSil gains EU label extension
This article was originally published in Scrip
Executive Summary
Nycomed's haemostatic sponge TachoSil has been granted an EU label extension. The product, a collagen patch coated with fibrinogen and thrombin coagulation factors,was originally approved for the supportive treatment in surgery for improvement of haemostasis where standard techniques have failed in 2004. The wider label includes indications for tissue sealing, as well as for the suture support in vascular surgery.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.